eVusheld Assessment reaL wORld effectiveness in DoD Health System - VALOR DoD
Study identifier:D8850R00016
ClinicalTrials.gov identifier:NCT05569408
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations in the United States Department of Defense Healthcare System
Medical condition
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Phase
Phase 4
Healthy volunteers
No
Study drug
EVUSHELD
Sex
All
Actual Enrollment
4724
Study type
Observational
Age
12 Years - n/a
Date
Study Start Date: 10 Aug 2023
Primary Completion Date: 22 Dec 2023
Study Completion Date: 22 Dec 2023
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Sept 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| EVUSHELD Arm Individuals given EVUSHELD for prophylaxis | Drug: EVUSHELD Tixagevimab (AZD8895) and cilgavimab (AZD1061) Other Name: AZD7442 |
| Concurrent Control Arms Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD | Drug: EVUSHELD Tixagevimab (AZD8895) and cilgavimab (AZD1061) Other Name: AZD7442 |
